What Mongoose Bio does

Mongoose Bio, Inc. is a private clinical-stage biopharmaceutical company headquartered in Houston, Texas (2450 Holcombe Blvd., Ste. 200), spun out of MD Anderson Cancer Center in 2023 under an exclusive worldwide license to develop and commercialize TCR-T cell therapy technology developed by founder Dr. Cassian Yee over more than 20 years. The company is developing a portfolio of four epigenetically reprogrammed autologous central memory T-cell (Tcm) therapies — lead asset MGB-001 plus pipeline candidates MGB-002, MGB-003, and MGB-004 — for common and rare solid tumors including gastric/esophageal, breast, non-small cell lung, prostate, bladder, cervical, and head/neck cancers. Its technical platform has two pillars: (1) the Immunopeptidome Discovery Platform (IDP), a mass-spectrometry-based system that has generated over 2 million spectra and empirically validated 250 high-value TCR target antigens with four selected candidates covering >80% of Class I MHC (HLA); and (2) Epigenetic T Cell Reprogramming (ECMR), an IL-21 and HDACi-based protocol that drives T cells into a central memory state for in vivo persistence without high-dose lymphodepletion, enabling outpatient-compatible treatment.

The company operates a B2B enterprise model targeting academic cancer centers, hospital systems, and oncology practices that will administer the cell therapies once approved. Current revenue streams are pre-commercial: future economics will come from one-time treatment delivery in clinical settings and from potential out-licensing or co-development royalties on the MD Anderson–licensed TCR-T IP. Manufacturing for the lead program is supported by CDMO partnerships with Cellipont Bioservices (cGMP cell therapy manufacture, agreement signed October 2024) and Matica Bio (lentiviral vector production, partnership signed October 2024). The company is led by CEO Neil Warma (appointed February 2024) and founder/CSO Dr. Cassian Yee, with a small team of 1–10 employees. As of late 2024, MGB-001 is positioned to enter a Phase 1 clinical trial; no products are approved or generating commercial revenue, and the company has filed an SEC Form D indicating private capital-raising activity.

Name

Mongoose Bio

Legal name

Mongoose Bio, Inc.

Website

https://mongoosebio.com

Company type

Private

Founded year

2023

Operating status

Operating

Headcount range

1–10 employees

Short description

Mongoose Bio is a clinical-stage biotech developing epigenetically reprogrammed autologous TCR-T cell therapies for solid tumors, leveraging a proprietary Immunopeptidome Discovery Platform and Epigenetic T Cell Reprogramming technology licensed exclusively from MD Anderson Cancer Center.

Ownership category

akta.pro rank

Product category

Cancer Immunotherapy

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI)

akta.pro secondary industries

Proteomics & Mass Spectrometry Services (HLAGANAB), Proteomics & Biomarker Analytical Testing (HLAGADAG)

Keywords

• TCR-T cell therapy
• Adoptive cell therapy
• Cancer immunotherapy
• Solid tumor treatment
• Epigenetic cell reprogramming

Headquarters

HQ city

Houston

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. TCR-T Cell Therapy Development and Commercialization: Development and potential commercialization of epigenetically reprogrammed autologous TCR-T cell therapies for solid tumors. The company is advancing a pipeline of four TCR-T candidates (MGB-001 through MGB-004) with lead asset MGB-001 entering Phase 1 clinical trials for multiple cancer indications. Revenue would be generated through treatment delivery in clinical settings upon regulatory approval.
2. Licensing and IP Royalties: The company holds an exclusive license from MD Anderson Cancer Center to develop and commercialize TCR-T technology worldwide. As the platform is further developed, out-licensing of technology or co-development partnerships may generate revenue streams.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

Mongoose Bio is a clinical-stage biopharmaceutical company developing epigenetically reprogrammed autologous central memory T cell (Tcm) therapies (TCR-T) targeting highly immunogenic pan-cancer solid tumor antigens. Its pipeline includes lead asset MGB-001 and three additional candidates (MGB-002, MGB-003, MGB-004) selected through its proprietary Immunopeptidome Discovery Platform (IDP), with manufacturing enabled by Epigenetic T Cell Reprogramming (ECMR) technology.

Product overview

Mongoose Bio is a clinical-stage biopharmaceutical company developing a portfolio of epigenetically reprogrammed memory T cell therapies (TCR-T) for solid tumors. The company's product suite includes lead asset MGB-001 plus pipeline candidates MGB-002, MGB-003, and MGB-004, all TCR-T therapies derived from their Immunopeptidome Discovery Platform (IDP) and manufactured using their Epigenetic T Cell Reprogramming (ECMR) technology. The IDP platform enables identification of tumor-specific targets, while ECMR reprograms central memory T cells to persist long-term in vivo, addressing key limitations of conventional CAR-T and TCR-T approaches.

Differentiator

Problem solved

Functional benefit

Products and services

• MGB-001 High-affinity autologous TCR-T cell therapy targeting a cancer-testis antigen expressed in over 60% of breast cancers and approximately 45% of prostate, lung, bladder, gastric, ovarian, and head/neck cancers. Presented by HLA-A2 and A3/A11 subtypes representing >60% of global cancer patients; no off-target activity observed. Designed for solid tumor oncology use.
• MGB-002 Pre-clinical TCR-T cell therapy candidate targeting prostate, TNBC, lung, colorectal cancers and chordoma; HLA-A2/A24 restricted.
• MGB-003 Pre-clinical TCR-T cell therapy candidate targeting breast cancer; HLA-A2/A3/A11 restricted.
• MGB-004 Pre-clinical TCR-T cell therapy candidate targeting AML, bladder, breast, cervical, esophageal cancers, lymphoma, sarcoma, angiosarcoma, anaplastic thyroid cancer, and glioblastoma; HLA-A2 restricted.

Quantifiable outcome

• Relapse rates as high as 60% despite complete remission following CAR-T cell therapy due to lack of T cell persistence
• +5 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Two partnerships are on record, tiered minor and core.

• NASA / CASIS / ISS National LaboratoryminorStrategic or Co-development Partner · 31 July 2024Mongoose Bio was invited to join a global consortium to study the effects of microgravity on human T-cells aboard the International Space Station. The consortium, including NASA, CASIS, Axiom Space, BioServe Space Technologies, Deep Space Biology, The University of Texas, and MD Anderson, aims to uncover novel signaling pathways and identify potential immune targets. Mongoose Bio's role is to translate findings to clinical development.
• MD Anderson Cancer CentercoreTechnology or IntegrationMongoose Bio was spun out of MD Anderson Cancer Center in 2023 with an exclusive worldwide license to develop and commercialize the TCR-T technology. The science and broad intellectual property were developed by Dr. Cassian Yee at MD Anderson over 20 years of research.

Scale indicators6 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Adaptimmune Therapeutics: Adaptimmune is a clinical-stage cell therapy company developing TCR-T cell therapies for solid tumors, including MAGE-A4 and other cancer-testis antigens. It is the most direct comparable to Mongoose Bio given shared TCR-T modality, solid tumor focus, and HLA-restricted target approach.
• Immatics: Immatics develops TCR-T and TCR-bispecific therapies directed at tumor-specific peptides identified through its XCEPTOR and XCUBE platforms, closely mirroring Mongoose Bio's mass-spec-based immunopeptidome discovery and TCR-T pipeline. Dr. Yee has also served as a scientific advisor to Immatics.
• Iovance Biotherapeutics: Iovance is the leader in tumor-infiltrating lymphocyte (TIL) therapy for solid tumors, with FDA-approved lifileucel for melanoma. Mongoose Bio explicitly positions its reprogrammed TCR-T approach against TIL therapies, making Iovance the most relevant comparator for solid-tumor cell therapy adoption and pricing dynamics.
• Marker Therapeutics: Marker Therapeutics develops multi-tumor-associated antigen (TAA)-specific T cell therapies for solid tumors and hematologic malignancies. Mongoose Bio's VP of Manufacturing previously led cell therapy manufacturing at Marker, and the companies share a TCR-based approach to broad solid tumor targeting.
• Achilles Therapeutics: Achilles Therapeutics develops personalized neoantigen-targeted T cell therapies for solid tumors using patient-specific TCR-T products. It is comparable to Mongoose Bio as a TCR-T platform for solid tumors, though Achilles focuses on patient-specific neoantigens rather than shared cancer-testis antigens.

Broad incumbents

• Allogene Therapeutics: Allogene is a leading allogeneic CAR-T developer with a broad pipeline across hematologic and solid tumor indications. While primarily CAR-T focused, it represents a major incumbent in cell therapy with manufacturing scale that could eventually compete in solid tumor settings where Mongoose Bio's TCR-T plays.
• BioNTech: BioNTech is a large commercial-stage biopharmaceutical company with a growing cell therapy pipeline including TCR-T candidates (e.g., BNT211 for CLDN6) for solid tumors. It represents a well-capitalized broad incumbent whose progress validates the TCR-T solid tumor thesis and sets competitive benchmarks.
• Sana Biotechnology: Sana Biotechnology is a clinical-stage cell therapy company developing engineered T cells and stem cell-based therapies. Its hypoimmune allogeneic platform and in vivo cell engineering programs make it a relevant broad incumbent peer in the next-generation cell therapy category where Mongoose Bio operates.

Emerging players

• Cellectis: Cellectis is a clinical-stage gene editing company developing allogeneic CAR-T and TCR-T cell therapies. Its TALEN-based gene editing platform and TCR-T pipeline make it a relevant adjacent peer for Mongoose Bio's engineered T cell approach, though it focuses on allogeneic rather than autologous products.
• Celularity: Celularity develops placental-derived allogeneic cell therapies including NK and T cell candidates for oncology. It represents an emerging player in the broader cell therapy oncology space where Mongoose Bio competes for talent, capital, and clinical trial site capacity.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/mongoose-bio-inc

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Mongoose Bio